LYEL VS ABBV Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend

Performance

LYEL
10/100

LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

ABBV
100/100

ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.

Technicals

LYEL
54/100

LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.

ABBV
11/100

ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

LYEL
100/100

LYEL has missed earnings 1 times in the last 20 quarters.

ABBV
100/100

ABBV has missed earnings 0 times in the last 20 quarters.

Profit

LYEL
10/100

Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ABBV
80/100

Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

LYEL
43/100

LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

ABBV
47/100

ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Analyst Price Targets

LYEL

"Analyst Price Targets" not found for LYEL

ABBV
68/100

20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.

Sentiment

LYEL

"Sentiment" not found for LYEL

ABBV
71/100

ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.

Dividend

LYEL

"Dividend" not found for LYEL

ABBV
100/100

ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Lyell Immunopharma, Inc. Common Stock Summary

Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ABBVIE INC. Summary

New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.